Form 4 for AQST Aquestive Therapeutics, Inc.
Accepted 2025-11-12 00:00:00 ET · period of report 2025-11-10 · accession 0001214659-25-016275 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-12 | 2025-11-10 | AQST | Davis Matthew W. | Chief Development Off | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
| D | 2025-11-12 | 2025-11-10 | AQST | Davis Matthew W. | Chief Development Off | A - Grant | $0.00 | +50.0K | 50.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-10 | A | A | 50,000 | $0.00 | 50,000 | D | — | — | (F1) The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-11-10 | A | A | 50,000 | $0.00 | 50,000 | D | $5.58 · — to 2035-11-10 | 50,000 Common Stock | (F2) The option will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment. |